Non-hormonal therapy of post-menopausal vasomotor symptoms: A structured evidence-based review

被引：69
作者：
Cheema D. [1 ]
Coomarasamy A. [2 ]
El-Toukhy T. [2 ]
机构：
[1] Royal Worcestershire Hospital, Worcester
[2] Assisted Conception Unit, Guy's and St. Thomas Hospital, Thomas Guy House, SE1 9RT London, St Thomas Street
来源：
Archives of Gynecology and Obstetrics | 2007年 / 276卷 / 5期
关键词：
Complimentary; Herbal and alternative therapy; Hormone replacement therapy; Menopause; Non-hormonal; Vasomotor symptoms;
D O I：
10.1007/s00404-007-0390-9
中图分类号：
学科分类号：
摘要：
Background: Interest in non-hormonal therapies for the treatment of menopausal symptoms has increased since the publication of adverse effects of estrogen replacement therapy. Objective: To provide information on the efficacy of non-hormonal therapies for menopausal vasomotor symptoms based on evidence from published randomised controlled studies. Methods: The Cochrane Database of Systematic Reviews (CDSR), MEDLINE, Alternative Therapies in Health and Medicine database (ATHMD) and Allied and Complementary Medicine database (AMED) were searched for randomised controlled trials in the English language reporting data on treatment of menopausal vasomotor symptoms. Trials including cancer breast patients were included. Results: Our search identified 58 randomised controlled trials of which 11 involved the use of clonidine, six for SSRIs, four for gabapentin, seven for black cohosh, seven for red clover, 18 for phytoestrogens, two for ginseng, one for evening primrose, one for dong quai and one for vitamin E. Most trials had methodological deficiencies. Conclusion: There is evidence that clonidine, paroxetine, venlafaxine, gabapentin and black cohosh may be beneficial in the treatment of menopausal vasomotor symptoms in some women. Current evidence does not support the use of fluoxetine, red clover, phytoestrogens, Ginseng, evening primrose, dong quai and vitamin E. The side effects profile of these therapies should be considered. © 2007 Springer-Verlag.
引用
收藏
页码：463 / 469
页数：6
相关论文
共 71 条
[21]  
Loprinzi C., Kugler J., Sloan J., Mailliard J., Lavasseur B., Barton D., Novotny P., Dakhil S., Rodger K., Rummans T., Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial, Lancet, 356, pp. 2059-2063, (2000)
[22]  
Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., Et al., Phase III evaluation of fluoxetine for treatment of hot flashes, J Clin Oncol, 20, pp. 1578-1583, (2002)
[23]  
Suvanto-Luukkonen E., Koivunen R., Sundstrom H., Citalopram and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized, 9-month, placebo-controlled, double-blind study, Menopuase, 12, pp. 18-26, (2005)
[24]  
Guttuso T.J., Kurlan R., McDermott M.P., Kieburtz K., Gabapentin's effect on hot flashes in postmenopausal women: A randomized controlled trial, Obstet Gynecol, 101, pp. 337-345, (2003)
[25]  
Pandaya K.J., Morrow G.R., Roscoe J.A., Zhao H., Hickok J.T., Pajon E., Sweeney T.J., Banerjee T.K., Flynn P.J., Gabapentin for hot flashes in 420 women with breast cancer: A randomized double-blind placebo-controlled trial, Lancet, 366, pp. 818-824, (2005)
[26]  
Reddy S.Y., Warner H., Guttuso T., Messing S., Digrazio W., Thornburg L., Guzick D.S., Gabapentin, estrogen and placebo for treating hot flushes: A randomized controlled trial, Obstet Gynecol, 108, pp. 41-48, (2006)
[27]  
Loprinzi C.L., Kugler J.W., Barton D.L., Dueck A.C., Tschetter L.K., Nelimark R.A., Et al., Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5, Clin Oncol, 25, pp. 308-312, (2007)
[28]  
Uebelhack R., Blohmer J.U., Graubaum H.J., Busch R., Gruenwald J., Wernecke K.D., Black cohosh and St. John's wort for climacteric complaints: A randomized trial, Obstet Gynecol, 107, pp. 247-255, (2006)
[29]  
Osmers R., Friede M., Liske E., Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms, Obstet Gynecol, 105, pp. 1074-1078, (2005)
[30]  
Wuttke W., Seidlove-Wuttke, Gorkow, The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: Effects on menopause symptoms and bone markers, Maturitas, 14, pp. 67-77, (2003)
12345678